Calavo Growers Posts Mixed Results in Q3

Calavo Growers (CVGW) reported Q3 FY2025 results with nearly flat overall revenue at $178.8 million and a slight non-GAAP EPS increase to $0.57. The Prepared segment significantly outperformed, achieving a 40% sales increase and a 201% gross profit surge, driven by higher volumes and operational efficiency. Conversely, the Fresh segment experienced an 8% drop in carton sales and a 32% decline in gross profit, primarily due to a one-time $4.2 million FDA detention hold cost on avocado imports, an issue now resolved. The company also benefited from reduced SG&A expenses following the resolution of major regulatory inquiries, highlighting operational resilience despite the one-off Fresh segment impact.

Analysis

Calavo Growers' Q3 FY2025 results depict a company with bifurcated performance, as overall revenue remained flat at $178.8 million (-0.4% YoY) while non-GAAP EPS rose slightly to $0.57. The key driver of underlying strength was the Prepared segment, which saw sales surge 40% and gross profit expand by 201%, fueled by a 35% increase in volume and improved operational efficiencies. Management's forward-looking commentary suggests this momentum will continue, with the segment annualizing at over $100 million in sales. In stark contrast, the core Fresh segment experienced an 8% decline in carton sales and a 32% drop in gross profit, primarily attributed to a one-time, non-recurring $4.2 million charge from a now-resolved FDA detention on avocado imports. While this charge was material, the segment also faced underlying pressure from lower volumes and pricing. Importantly, the company demonstrated operational discipline by reducing SG&A expenses by 12.4%, aided by the resolution of the FDA matter and a separate FCPA inquiry, which removes significant legal and regulatory overhang. The balance sheet remains strong with $63.8 million in cash and minimal debt, supporting a stable $0.20 quarterly dividend.

Key Decisions for Investors

• Evaluate the investment thesis based on the divergence between the high-growth, high-margin Prepared segment and the volume-challenged Fresh segment, whose underlying performance ex-one-time costs remains a key variable.
• Recognize that significant near-term risks have been mitigated with the resolution of the FDA detention and FCPA inquiry, and monitor for a potential positive catalyst from the pending insurance claim recovery for the $4.2 million loss.
• Consider the strong balance sheet and stable $0.20 quarterly dividend as support, while closely tracking Fresh segment volume and pricing in coming quarters to validate that the recent disruption was temporary and not a structural decline.